Profile of Drug Use in Outpatients with Multidrug Resistant Tuberculosis (MDR TB) at RSD dr. Soebandi Jember
DOI:
https://doi.org/10.36858/ipj.v1i2.22Keywords:
Drug use profile;, Multidrug Resistant Tuberculosis;, RSD dr. SoebandiAbstract
Background: A drug use profile is a description of a drug that can be identified through its characteristics. Multidrug Resistant Tuberculosis (MDR TB) is a tuberculosis disease caused by Myrobacterium Tuberculosis bacteria against two types of OAT drugs, namely rifampicin and isoniazid.
Objective:The aim of this study was to determine the profile of drug use in outpatients with Multidrug Resistant Tuberculosis (MDR TB) at RSD dr. Soebandi Jember for the 2023 period.
Method:This research is descriptive research with one variable. The research sample was 70 MDR TB outpatients using a random sampling technique.
Results: In the results for gender characteristics, the number of male patients was 46 (62%), female 28 (38%). Ages 17-25 years amounted to 10 (13%), ages 26-45 years 31 (42%), ages > 46 years 33 (45%). Length of treatment in initial stage 18 (24%), advanced stage 56 (76%). Combination of 3 drugs bedaquiline - linezoid - cycloserine 14 (31%), bedaquiline - ethambutol - cycloserine 1 (2%), clofazimine - linezoid - bedaquiline 1 (2%), bedaquiline - levofloxacin - ethambutol 14 (31%), ethambutol - levofloxacin - cycloserine 13 (30%), bedaquiline - cycloserine - linezoid 2 (4%), combination of 4 drugs levofloxacin - bedaquiline - ethambutol - clofazimine 10 (34%), clofazimine - ethambutol - bedaquiline cycloserine 12 (42%), clofazimine - bedaquiline - ethambutol - ethionamide 7 (24%). The drug use profile contained 7 types of drugs, namely lefoxloxacin 36 (14%), bedaqualin 60 (24%), Ethambutol 57 (23%), Clofazimine 31 (12%), cycloserine 42 (17%), Linezolid 17 (7%), Ethionamide 8 (3%).
Conclusion:In the results, the highest number of male gender characteristics was 46 people (62%), the highest age characteristic was >46 years, 33 people (45%), the highest length of treatment characteristic was the advanced stage, namely the advanced stage, 56 people (67%) , the characteristics of the combination of drugs that are widely used are a combination of 3 drugs, there are 2 groups, including 14 people (31%) of bedaquiline - lienezoid - cycloserine and 14 people (31%) of bequiline - levofloxacin - ethambutol, the profile of the most widely used drug is bedaquiline 60 people (24%).
References
Alqadri, AZ (2020). Profile of Drug Use in Pulmonary Tuberculosis Sufferers in the Outpatient Installation of North Sumatra University Hospital (Doctoral dissertation, North Sumatra University).
Aminah S., 2014, Evaluation of the Use of Antituberculosis Drugs in Multi Drug Resistant Tuberculosis Patients at Hospital X Period January – June 2013. Muhammadiyah University of Surakarta.
Anastasia, ASR (2018). The Relationship between Compliance and the Incidence of Multidrug Resistant Tuberculosis (MDR TB) at Manguharjo Madiun Lung Hospital.
Chisholm-Burns MA, Schwinghammer TL, Wells BG, Malone PM, Kolesar JM and DiPiro JT, 2016, Pharmacotherapy Principles & Practice, 4th ed., McGraw Hill Education, United States of America.
Ministry of Health, 2007, National Guidelines for Controlling Tuberculosis, Ministry of Health of the Republic of Indonesia, Jakarta
Emmi Bijawati, SKM., MK, Munawir Amansyah, SKM., MK, & Nurbiah, S. (2018). The Risk Factors for Treatment of Multidrug Resistance Tuberculosis (MDR-TB) Patients in Labuang Baji General Hospital Makassar in 2017. National Journal of Health Sciences, 1(1), 1–17.
Farida. (2020). Successful factors in the treatment of Multi Drug Resistance Tuberculosa (MDR-TB) in Indonesia: Systematic Review Successful factors in the treatment of Multi Drug Resistance Tuberculosa (MDR TB) In Indonesia: Systematic Review. JHECDs, 6(1), 35–41.
Francis, J. (2011). Drug Resistant Tuberculosis: A Survival Guide for Clinicians 2nd Edition. California: Curry National Tuberculosis Center
Hirpa S., Medhin G., Girma B., Melese M., Mekonen A., Suarez P. and Ameni G., 2013, Determinants of multidrug-resistant tuberculosis in patients who underwent first-line treatment in Addis Ababa : a case control study, Biomedcentral, 1–9.
Kamal, P., & Maudina, L. (2020). Study of the Causes of Tuberculosis Patients No
Complete Routine Treatment at a Health Facility.
Ministry of Health of the Republic of Indonesia, 2011, Rational Drug Use Module, Ministry of Health of the Republic of Indonesia, Jakarta.
Ministry of Health of the Republic of Indonesia, 2014a, National Guidelines for Tuberculosis Control, Ministry of Health of the Republic of Indonesia, Jakarta.
Ministry of Health of the Republic of Indonesia, 2014b, Technical Guidelines for Integrated Management of Drug-Resistant Tuberculosis Control, Jakarta.
Lemos ACM and Matos ED, 2013, Multidrug-resistant tuberculosis, Brazilian Journal of Infectious Diseases, 17 (2), 239–246.
1Masrifah, D., Andarini, YD, & Kusumaningtyas, NM (2020). Evaluation of the Use of Anti-Tuberculosis Drugs in Outpatient Tuberculosis Patients at the Caruban District Hospital for the Period January-March 2018 Pharmaceutical Journal of Islamic Pharmacy.
Nugroho, FS, Shaluhiyah, Z., & Adi, S. (2018). Description of Treatment Behavior of MDR TB Patients in the Intensive Phase at Dr Moewardi Hospital, Surakarta. Health Journal.
Utari BND, Pambudi, RS, & Khusna, K. (2022). Profile of the Use of Antituberculosis Drugs (Oats) in Ngemplak Community Health Center, Boyolali Regency in 2021 (Doctoral dissertation, Sahid University Surakarta).
WHO, 2012, Multidrug-Resistant tuberculosis (MDR-TB) www.who.itb/tb (accessed 15 July 2013).
World Health Organization. (2014). Companion Handbook to The WHO: Guidelines for the Programmatic Management of Drug Resistant Tuberculosis. Switzerland: WHO Publications
World Health Organization, 2013, Global Tuberculosis Report 2013, WHO Library Cataloging.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Nindri Lusiana Safana Nindri Lusiana Safana, Sholihatil Hidayati
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
